The Effect of Modified Radical Endoscopic Sinus Surgery on Eosinopilic Chronic Rhinosinusitus With Nasal Polyps

Inclusion Criteria:

• CRSwNP is diagnosed according to EPOS clinical guidelines and met surgicalrequirements, the blood eosinophil count was greater than 0.22;

• Subjects/legal authorized representatives must understand the purpose and proceduresof the study and voluntarily sign the informed consent, voluntarily participate inthe study and comply with the study regulations, understand and comply withfollow-up plan, and can correctly record the scale score, the administrationfrequency, accompanying drug use and adverse events, etc;

• The examinee must be 18-65 years old, male or non pregnant female, limited toChinese;

• During the treatment and follow-up period, female subjects have no pregnancy andlactation plans;

• The subjects did not participate in other clinical trials in the past three monthsand agreed not to participate in other clinical trials before reaching the end pointof this trial;

• Patients accompanying asthma must use their regular asthma treatment steadily in thepast 6 weeks;

Exclusion Criteria:

• Women must not be pregnant, or breast-feeding;

• Subjects with cystic fibrosis, congenital ciliary dyskinesia, fungal sinusitis,systemic vasculitis and granulomatous disease, tumor, and immunodeficiency areexclued;

• Subjects accpted nasal endoscopic surgery within 6 months are exclued;

• Subjects with an upper respiratory tract infection within 4 weeks of entering thestudy are excluded;

• Subjects with serious metabolic, cardiovascular, autoimmune, neurology, blood,digestive, cerebrovascular, or respiratory system disease, or any diseaseinterfering with the evaluation of results or affecting subjects safety areexcluded, such as glaucoma and tuberculosis;

• Currently participating in other clinical studies or in other clinical investigatorswithin 30 days, or staff directly involved in this study;

• Subjects with emotional or mental problems are excluded;

• Subjects must not have received immunotherapy within the previous 3 months;

• Subjects unsuitable for inclusion based on judgement of researchers are excluded;